| Gene symbol | VEGFA | Synonyms | L-VEGF, MVCD1, VEGF, VPF | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | vascular endothelial growth factor A | ||||
| GTO ID | GTC1421 |
| Trial ID | NCT01589718 |
| Disease | Proliferative Diabetic Retinopathy |
| Altered gene | VEGFA |
| Therapeutic/Target gene | Target gene |
| Therapy | Aptamer |
| Treatment | Macugen|pegaptanib|EYE001 |
| Phase | Phase3 |
| Recruitment status | Withdrawn |
| Title | A Phase III Randomized 1:1, Masked, Study of the Safety, Tolerability, and Efficacy of Intravitreal Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Adjuvant Management of TRD and Vit Hem Associated With PDR |
| Year | 2012 |
| Country | United States |
| Company sponsor | Greater Houston Retina Research |
| Other ID(s) | No-Crunch 01 |
| Cohort1: Macugen | |||||||||
|
|||||||||
| Cohort2: Sham injection | |||||||||
|
|||||||||